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in valvular AF and are therefore not suitable for use in this 
context. The definition of non-valvular AF has been conten-
tious; however in an effort to standardise definitions, De 
Caterina, et al. have suggested the term ‘mechanical and 
rheumatic mitral valvular AF (MARM-AF) to represent valvular 
AF. Patients with AF and bio-prosthetic valves in the aortic 
position (and those with mitral valve repair) or mitral regur-
gitation or hypertrophic cardiomyopathy, do not appear to 
have an increased additional risk of thromboembolism.(3) This 
definition will be adopted for this review.
DIAGNOSING ATRIAL FIBRILLATION
An ECG is required to confidently diagnose AF. This can be a 
straightforward process, if the patient is in AF at the time; 
however, as AF can be paroxysmal, documenting the arrhythmia 
on ECG can be challenging. Ambulatory ECG monitoring in 
the form of Holter recording can be useful, but sometimes 
prolonged monitoring may be required. Novel technologies, 
such as implantable loop recorders or event recorders, may be 
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NON-
VALVULAR AF
Atrial fi brillation is the most common clinical 
arrhythmia. 
The mainstay in the prevention of atrial fi brillation 
related stroke is oral anticoagulation. The 2 most 
important aspects in the management of patients with 
atrial fi brillation, is therefore risk stratifi cation for 
stroke and risk assessment for bleeding. Assessment 
of risk factors is in fact a dynamic process. In appro-
priate patients, novel anticoagulants are safe and better 
tolerated, and may be considered as an alternative to 
warfarin. In patients who are truly intolerant of, or 
where an absolute contra-indication to anticoagulation 
exists, occlusion of the left atrial appendage may be 
considered. Patients are to be carefully counselled with 
regards this therapy as currently, questions surrounding 
its safety and long-term effi ciency remain unanswered. 
This is an area of on-going research and further evidence 
is awaited. 
Catheter ablation of atrial fi brillation is a highly effective 
therapy to achieve freedom of recurrent arrhythmia 
and relief from symptomatic atrial fi brillation. Recent 
systematic reviews demonstrate a low incidence of 
periprocedural complications with regards catheter 
ablation of atrial fi brillation, with acute complication 
rates having decreased signifi cantly in recent years. 
This may be attributed to increasing experience and 
improved catheter technology.  SAHeart 2015;12:66-73
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INTRODUCTION
Atrial fibrillation (AF) is the most common cardiac arrhythmia 
affecting approximately 1-2% of the population in the developed 
or western world. There is a dearth of data on the prevalence 
of AF in Africa, small studies have indicated a figure of 0.7%, 
but this is likely to be an underestimate.(1) Moreover, it is likely 
that this figure will rise with an ageing population, and there-
fore AF will become an important public health issue.
The RELY-AF registry provides contemporary data on AF risk 
factors and anticoagulation in Africa. The key findings being 
that, compared to Europe and North America, patients were 
younger and had a much higher prevalence of rheumatic heart 
disease. Nevertheless, hypertension appeared to be a stroke 
risk factor associated with AF. Furthermore, anticoagulation 
rates were lower in comparison compared (40-50%) despite a 
higher prevalence of rheumatic heart disease. Interestingly INR 
control (i.e. 2-3) was better compared to South America and 
South East Asia (41%), but countries in the developed world 
had modestly better rates averaging 60%. Whilst this data is 
interesting, it is important to note that just over 1 000 patients 
were studied, therefore larger population studies are needed to 
clarify these findings.(2)
The definition of non-valvular AF is important as patients with 
valvular AF have a higher risk (with specific reference to 
rheumatic mitral stenosis and prosthetic mechanical valves)(3) of 
thrombus formation, and that NOACs have not been tested 
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necessary for rhythm recording. A particular challenge is the 
asymptomatic patient with AF. Opportunistic screening, e.g. 
pulse checks or ECGs done as part of health checks or annual 
reviews in patients with conditions like hypertension may be 
necessary. Although AF can be asymptomatic, the stroke risk it 
confers is no different to patients who have symptoms.
Implantable devices (including loop recorders) have increased 
the detection of AF. Studies suggest that the stroke risk is 
related to the burden of AF(4) and that, in patients with 
paroxysmal AF, the period when patients go into AF may pose 
the highest stroke risk. Controversies exist as to the minimum 
burden of AF that is required to institute anticoagulation, as 
even a few minutes can be sufficient in certain patients.(5) Indeed 
in patients who have suffered ischaemic stroke (>40 years old), 
AF was detected in 12% of patients who were implanted with 
a loop recorder by one year, compared to 2% without.(6) This 
does raise issues as to how hard we look for AF in patients who 
are potentially vulnerable, or whether patients with additional 
risk factors such as smoking, hypertension, diabetes and obesity 
should be treated upfront?
AETIOLOGICAL RISK FACTORS IN ATRIAL 
FIBRILLATION(7)
AF is a complex arrhythmia, and although there may be little in 
the way of difference in ECG appearance between patients, the 
aetiology and prognosis may differ markedly. This, in part, is 
reflected by the way in which AF is managed clinically - from 
accepting it as permanent and not pursuing sinus rhythm, to 
extensive atrial ablation and complex surgical procedures.
The discovery of the importance of the pulmonary vein/left 
atrial junction mediating AF, and the finding that AF can be 
potentially cured by eliminating the focus, has been central to 
the increase in the use of catheter ablation.(8,9) Broadly AF can 
be thought of as trigger dependent due to electrical instability 
(e.g. tissue inhomogeneity at the left atrial/pulmonary vein 
junction) and AF perpetuation because of abnormal atrial 
substrate (e.g. fibrotic scar secondary to chronically elevated 
left ventricular end diastolic pressure). The majority of patients 
probably have both mechanisms present, with the added insult 
from AF itself causing further electrical and structural (negative) 
remodelling - AF begets AF. A basic concept of these mecha-
nisms is helpful when attempting to understand the manage-
ment of AF.
Trigger dependent AF is usually paroxysmal, but if the atrial 
tissue remodels then the episodes can become longer and 
more persistent. An increase in left ventricular end diastolic 
pressure results in an increase in atrial pressure, hypertrophy 
and stretch as well as the development of scar tissue. It is 
therefore not surprising that hypertension and heart failure are 
commonly associated with AF. However, patients with normal 
pressures can also develop AF and it is now recognised that 
certain patients can have a primary atrial cardiomyopathy, 
resulting in gross atrial scarring and AF. Furthermore, AF can 
run in families where a number of genes have been implicated 
affecting ion channels; this adds “electrical” substrate as another 
factor in the causation of AF. Non-valvular AF therefore covers 
a complex spectrum of heterogeneous, overlapping phenotypes. 
The importance of these varied mechanisms is that the 
treatment of AF not only involves rhythm management but 
the treatment of conditions that predispose to AF, even before 
AF develops.
PATHOPHYSIOLOGY OF ATRIAL FIBRILLATION
The fibrillating atrium transforms a chamber that fills and 
empties in a co-ordinated fashion to an essentially still com-
partment. In addition, the rapid activity transmitted to the AV 
node results in an irregular and rapid ventricular response. 
Whilst ventricular filling is mainly passive, loss of atrial con-
traction can result in a 20% reduction in cardiac output. 
Furthermore, rapid and irregular ventricular contraction impairs 
ventricular filling and further reduces cardiac efficiency.(10) 
Loss of atrial contractility reduces atrial flow. As discussed 
before, many of these patients have abnormal substrate and 
therefore abnormalities in atrial structure. Moreover, conditions 
such as diabetes and hypertension are not uncommon in AF 
and are pro-inflammatory states. These factors constitute 
Virchow’s triad for thrombogenesis and thus explain why AF is 
associated with thrombus formation in the atria and thrombo-
emolism. The left atrial appendage is the origin of most clots.
STRATEGIES TO PREVENT NON-VALVULAR 
ATRIAL FIBRILLATION
Primary prevention
Early and optimal management of conditions that predispose to 
AF such as heart failure, hypertension and diabetes intuitively 
could prevent the onset of AF by limiting the exposure of the 
atrium to high left ventricular end diastolic pressure. The LIFE 
trial suggested a potential role in the use of angiotensin 2 
receptor blockers in primary prevention.(11) These drugs, that 
are not anti-arrhythmic agents, are generally referred to as 
upstream treatment. There is some supportive data for the use 
of atorvastatin in the prevention of AF post cardiac surgery, 
but patients need to be on it beforehand.(12) 
Secondary prevention
Once AF has developed there is little data to support upstream 
drug therapy in preventing further episodes of AF. Early 
treatment of AF, for example when paroxysmal, could poten-
tially attenuate negative remodelling as AF begets AF. There is 
however a lack of data to support this currently, and in the 
majority of patients the effect of pre-existing conditions (e.g. 
hypertension, sleep apnoea) may have a much greater negative 
impact, even after AF ablation.(13,14)
Recent data from the LEGACY trial has suggested that patients 
who are overweight and receive a planned management 
strategy to lose weight appear to benefit with not only improved 
rhythm control, but quality of life. At least 10% weight loss, 
which is then sustained is required, but this data is encouraging 
because it is a particularly relevant secondary prevention strat-
egy when the prevalence of obesity worldwide is increasing.(15)
MANAGEMENT OF NON-VALVULAR ATRIAL 
FIBRILLATION
Two key issues that need to be addressed in patients with 
AF are how to prevent thromboembolic complications and 
whether to offer rate or rhythm control. 
Prevention of thromboembolic complications
In any patient with AF, the risk is greater (at least 5 times) than 
that in a similar subject in sinus rhythm.(7) The most common 
complication is stroke; however, embolism can occur anywhere 
in the systemic circulation for example the small bowel. 
Outcomes, including mortality in patients who have stroke as 
a result of AF, are often worse than in those who do not have 
AF; the consequences are far more costly than in patients with 
sinus rhythm.(16) The cornerstone of management is the pre-
vention of thrombus formation, through the use of anti-
thrombotic therapy which includes antiplatelet agents or 
anticoagulation. It has now been increasingly recognised that 
anti-platelet treatment confers no benefit in stroke prevention 
and can result in harm. The prescription of these drugs is 
therefore not recommended by current guidelines.(17,18) 
Oral anticoagulation unfortunately predisposes to an increase in 
bleeding risk, and therefore in an individual the risk/benefit of 
bleeding versus thrombotic complications has to be carefully 
considered. The key question is not who to anticoagulate, but 
to identify the patient who is at very low risk and in whom 
anticoagulation will not be beneficial. Various scoring systems 
have been developed over the years with initial classification 
into low, medium and high risk followed by the CHADS2 score. 
This score has now been updated by CHA2DS2VaSc which 
includes vascular disease and increases weighting in patients 
over 75 and females (provided they have another risk factor).(19) 
Both the CHA2DS2VaSc and HASBLED scores are used in 
assessing the risk of stroke, and bleeding, respectively (Table 1). 
In essence, in the setting of AF, an individual requires a score 
of 1 (if male) and 2 (if female) to warrant anticoagulation. 
Categories such as hypertension are in fact shared between 
the scoring systems. Regardless of the HASBLED score, (and 
in particular in the setting of multiple modifiable risk criteria 
here), oral anticoagulation is still recommended by current 
guidelines if the individual qualifies by the CHA2DS2VaSc 
score.
Following the consideration of the risks of thrombo-embolism 
and bleeding, systemic anticoagulation is considered, and 
Vitamin K antagonists such as warfarin are prescribed. It is very 
clear from clinical data that systemic anticoagulation signifi-
cantly reduces the risk of stroke in patients with AF, and the 
threshold of initiating treatment has been lowered over the last 
few years. Stroke in patients with AF is associated with greater 
mortality and disability, and hence investment in anticoagulation 
is cost effective.
Vitamin K antagonists operate with a narrow therapeutic index, 
and the dose response curve varies markedly from patient to 
patient. Therefore monitoring is required in the case of warfarin 
with INR. Because of the unpredictable pharmacodynamics of 
Vitamin K antagonists, together with the fact that their actions 
could be modified by diet (alcohol, leafy vegetables), medication 
(e.g. amiodarone) and by lack of compliance, a not uncommon 
problem is suboptimal INR control (either too high or too low). 
To an extent the morbidity with sub-therapeutic anticoagula-
tion is worse than with over-anticoagulation.(20) 
The concept of time in therapeutic range (TTR) has recently 
been a topical issue with the development of novel oral 
anticoagulants or non-vitamin K dependent oral anticoagulants 
(NOACs). Data from Rely-AF show South African patients to 
only have been within TTR approximately 58% of the time. It is 
also pertinent to note that South Africa was the only country 
from the African continent in fact represented in the study. This 
index (TTR) calculated the time that patients have maintained 
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TABLE 1: Assessing risk for stroke and bleeding using 
the CHA2DS2VaSc and HASBLED scores
Adapted from Lip G, et al. Chest 2010;137:263-72; Lip G, et al. Stroke 2010;41:
2731-8; Camm, J et al. Eur Heart J 2010;31:2369-429; Hart RG, et al. Ann Intern Med 
2007;146:857-67 and Pisters R, et al. Chest 2010;138:1093-100; ESC guidelines: 
Camm J, et al. Eur Heart J 2010;31:2369-429.
CHA2DS2-VASc
CHA2DS2-VASc criteria Score
CHF/LV dysfunction 1
Hypertension 1
Age ≥75 years 2
Diabetes mellitus 1
Stroke/TIA/TE 2
Vascular disease 1
Age 65-74 years 1
Sex category (i.e. female gender) 1
Max score 9
HAS-BLED
HAS-BLED risk criteria Score
Hypertension 1
Abnormal renal or liver function (1 point each) 1 or 2
Stroke 1
Bleeding 1
Labile INRs 1
Elderly (e.g. age ≥65 years) 1
Drugs  1
Alcohol 1
Max score 9
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a therapeutic INR level over a period of time, and the better 
the TTR the greater the efficacy of oral anticoagulation.(21) 
Considerable research efforts have been made to develop 
anticoagulants that do not require therapeutic monitoring and 
provide effective anticoagulation. Dabigatran, a direct thrombin 
inhibitor, was the first agent to be tested in a clinical trial and 
compared against warfarin. The key findings were that it was 
non-inferior, and the higher dose was potentially better than 
warfarin.(22)
Three other agents have been compared to warfarin in clinical 
trials since then. These are all factor Xa inhibitors and include 
apixaban,(23) rivaroxaban(24) and edoxaban.(25) These agents offer 
similar advantages to dabigatran. There appears to be a clear 
non-inferiority effect, and a potential superiority effect, espe-
cially when the TTR is taken into account. Table 2 summaries 
the key features of currently used NOACs.
Since there have been no head to head trials between different 
NOACs, it is very difficult to be definitive about which one to 
use, especially as their results are quite comparable. There are 
however certainly patients for whom warfarin use may still be 
preferable and these include:
 ■ Patients for whom NOAC use will lead to an unacceptable 
increase in cost.
 ■ Patients, already on warfarin, who do not mind periodic 
INR checks and who have had relatively easy INR control.
 ■ Patients with severe chronic kidney disease who have an 
estimated CrCl (creatinine clearance) less than 30mls/min.
 ■ Patients where NOACs are contra-indicated e.g. those on 
anti-epileptic or protease-inhibitor based anti-retroviral 
therapy agents.
A number of meta-analyses support the concept that NOACs 
are, in fact, preferable to warfarin in many cases. These are 
based on the findings that NOACs are associated with a 
significant reduction in intra-cranial haemorrhage, stroke/
systemic embolism as well as a marked reduction in haemor-
rhagic stroke and a trend towards reduced major bleeding.(26) 
Nevertheless, Vitamin K antagonists clearly have advantages 
over NOACs as well (Table 3).
Clinicians certainly need to familiarise themselves with the host 
of drug interactions and dosing schedules, for example in 
chronic kidney disease, applicable to these agents. It is highly 
recommended that rivaroxaban needs to be taken with food, 
for instance. 
An extensive description, including recommendations for 
transitioning of these agents, or that involving pending surgery, 
unfortunately falls beyond the scope of this article.  
As regards the future of anticoagulation in AF, new work on 
factor XI inhibitors looks very promising.
In patients with persistent AF undergoing cardioversion, current 
guidelines recommend a minimum period (at least 3 weeks) of 
therapeutic anticoagulation. This can be difficult to achieve 
quickly with drugs like warfarin. However as NOACs achieve 
therapeutic levels quickly and require no monitoring, as long as 
the patient is compliant, it can be assumed that therapeutic 
levels have been achieved over the minimum time period. 
Furthermore, patients do not need cardioversion postponed 
because of sub-therapeutic INRs. Cardioversion is now routinely 
performed on these agents and appears as safe as on warfarin 
with randomised control data (on rivaroxaban).(27,28)
Certain patients may not be able to tolerate oral anticoagula-
tion or may be at high risk of bleeding. Unfortunately many of 
these have a high risk of thromboembolism. Recent develop-
ments have focussed on either internal or extrinsic occlusion of 
the left atrial appendage. PROTECT AF was a randomised trial 
comparing warfarin versus left atrial appendage occlusion in 
non-valvular AF. Approximately 4 year follow up data suggest 
that the ischaemic stroke rate is similar in both groups, but that 
there are fewer haemorrhagic complications in the device 
TABLE 2: The NOACs
*All require dose adjustments in renal impairment. These drugs’ effects can be 
potentiated by CYP-3A4 and P-glycoprotein inhibitors and vice versa; it is important to 
check the formulary.
 Dabigatran Rivaroxaban Apixaban Edoxaban
Mechanism  Direct Direct factor Direct factor Direct factor
of action thrombin Xa inhibitor Xa inhibitor Xa inhibitor
 inhibitor
Dose* 150mg bd 20mg od 5mg bd 60mg od
Superiority  150mg bd Non-inferior Yes Not tested
over   only
warfarin for 
thrombo-
embolism    
Reduced  More with No Yes Yes
major  150mg bd
bleeding 
when 
compared to 
warfarin
TABLE 3: Advantages and disadvantages of NOACs 
when compared to warfarin
Advantages
Convenience (no routine 
INR checks)
Reduction in intracranial 
haemorrhage risk
Less susceptibility to drugs and 
dietary interactions
Shorter plasma half-life
Disadvantages 
Lack of blood level monitoring and 
compliance
Lack of approved antidote
Restrictions in severe chronic 
kidney disease
Higher cost 
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group.(29) Several other endocardial devices are available, and 
percutaneous as well as surgical clipping of the left atrium is 
possible. Although the treatments are new, they offer promise, 
especially in high risk bleeding patients. It is highly unlikely that 
device therapy will replace anticoagulation since there is an 
acute complication rate, and long term real world data is still 
awaited. Patients need careful counselling before this treatment 
is considered. Also of note is that the most recently updated 
AHA/ACC/HRS guidelines make no recommendation for per-
cutaneous approaches with specific reference to either LARIAT 
or the Watchman LAA occlusion device and that for surgical 
incision of the LAA in patients undergoing cardiac surgery, a 
single class 2B, level of evidence C, is given, reflecting the fact 
that the quality and quantity of data are simply limited.(17) 
Complications related to anticoagulants are generally treated 
according to the individual institution’s bleeding management 
protocol. General measures, including withholding the antico-
agulant (the NOACs have relatively short half-lives), ensuring 
adequate haemostasis and colloid resuscitation (including 
platelet/RBC or plasma administration) while simultaneously 
maintaining a sufficient diuresis, are often initially employed, 
depending on the severity of the bleeding and the specific 
anticoagulant used. Fresh frozen plasma rapidly restores coagu-
lation in the case of VKAs whereas vitamin K usually has a slow 
onset of action. Often misleadingly referred to as an “antidote” 
for VKAs, vitamin K restores physiological clotting factor syn-
thesis via a slow, complex process with clinically significant 
variability between patients. The INR corrects more quickly 
than the coagulopathy. 
In the case of the NOACs obtaining critical information with 
regards to dosing regimens, last intake and renal function is 
mandatory and may be ultimately lifesaving as time is often the 
most important antidote. There is some anecdotal evidence 
that, in addition to the general measures mentioned above, 
administration of oral charcoal (NOAC intake within 2 hours), 
tranexamic acid, desmopressin, prothrombin complex and 
recombinant factor VIIa may be of some use in major life-
threatening bleeding though the evidence base for any of the 
afore-mentioned is rather scanty.(30)
Uniquely, in the case of dabigatran, haemodialysis may be of 
use. More importantly, however, the humanised monoclonal 
antibody idarucizumab will almost certainly become available 
shortly as FDA approval is now pending. After IV administration 
(2-4g), it has a very rapid onset of action and demonstrates an 
instantaneous, specific and sustained reversal of antico-agulation 
that returns the patient to haemostasis. This effect seems 
independent of age, gender or degree of renal impairment and 
re-administration of dabigatran 24 hours afterward restores 
anticoagulation fully. Currently available data has suggested 
excellent efficacy and shown safety in healthy volunteers.(31,32)
Rate or Rhythm Control
Rate control is the initial step in the management of 
patients with persistent AF. Use of drugs that block the AV 
node, such as beta blockers or rate limiting calcium channel 
antagonists (diltiazem, verapamil), are usually first line and 
combination therapy can be considered. The role of digoxin 
is currently controversial as there have been conflicting reports 
of increased mortality.(33) It only exerts a modest rate control 
effect. Amiodarone or dronaderone do reduce heart rate, but 
are generally unsuitable because of long term drug toxicity. 
Further, dronaderone was associated with increased mortality 
in patients with permanent AF.(34)
For patients who are asymptomatic this strategy is sufficient. In 
those patients who are not considered to be candidates for 
rhythm control where rate control is difficult (and there are 
drug intolerances), implantation of a pacemaker followed by AV 
node ablation is an effective strategy. Patients with sympto-
matic paroxysmal AF may be prescribed beta blockers or 
calcium channel antagonists to reduce the heart rate when 
they experience intermittent symptoms.(7)
As demonstrated in the RACE II trial, in patients with permanent 
AF, a lenient rate control, strategy (resting heart rate ≤110bpm) 
is as effective and easier to achieve than that of a strict (resting 
heartrate ≤80bpm) strategy.(35)
The decision regarding rate or rhythm control is principally 
driven by symptoms. The AFFIRM and RACE trials demon-
strated that rate control was non-inferior to rhythm control 
and maintenance of sinus rhythm was poor.(36) Rhythm control 
strategies were therefore thought to be less useful; however, 
clinicians in favour of rhythm control argued that rhythm control 
strategies did not show more benefit because sinus rhythm was 
either not maintained or that there was morbidity and side 
effects from anti-arrhythmic drug therapy. Therefore, patients 
who may benefit from this strategy may be denied the bene-
ficial effects. 
Certain anti-arrhythmics utilised in the maintenance of sinus 
rhythm in AFFIRM, in particular amiodarone, were in fact asso-
ciated with increasing mortality. AFFIRM had also suggested 
significantly better symptomatic relief, in particular in heart 
failure patients where a rhythm control strategy was pursued.(37) 
This has also been re-iterated in very recent studies where AF 
ablation providing a rhythm control strategy offered heart 
failure cohorts a significantly improved quality of life, reduced 
hospitalisation and modestly increased survival.(38) In summary, 
analysis of AFFIRM trial data advocate that rhythm control 
strategies do offer a survival advantage over one of rate control, 
if only, however, this could be safely achieved. The search 
therefore, for more efficacious and safer strategies to enable 
and maintain the unquestionable benefit of sinus rhythm, 
continues.(35) 
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Moe, et al. proposed a multiple wavelet hypothesis in AF, 
and argued that atrial substrate modification may prevent 
AF perpetuation and encourage sinus rhythm. Surgical AF 
treatment initially involved cutting and sewing the atria to 
create lines of block. However, the technique requires open 
heart surgery and is technically demanding, and was performed 
in patients undergoing concomitant cardiac surgery, mainly 
valvular.(37)
In 1999 a seminal publication(8,9) by the Bordeaux electro-
physiology group changed the way rhythm control strategies 
would evolve. They showed that AF was triggered mainly by 
the pulmonary veins and that isolation of these veins using 
radiofrequency ablation catheters could terminate and prevent 
further episodes of paroxysmal AF.(39) As ablation was per-
formed in the veins, the risk of pulmonary vein stenosis was 
high and further development of this technique, using 3 
dimensional atrial geometry creation, involved creating wider 
lesions more atrially, to isolate the pulmonary veins, reduced 
this complication.(40) This technique was further modified to 
treat patients with persistent AF.(41) The use of percutaneous 
catheter ablation has been increasing exponentially over the 
last 10 years, and as the majority of patients with non-valvular 
AF do not need surgery, catheter ablation is a particularly 
attractive option. Initially the indications for this procedure 
were confined to those patients who had failed multiple anti-
arrhythmic agents, now it can be offered to patients who may 
not want to take long term medication or in whom drugs cause 
side effects.
Current ESC guidelines, as well as ACC/AHA guidelines, 
recommend the following:(42,17)
 ■ AF ablation may be considered a first line therapy in patients 
with symptomatic paroxysmal AF.
 ■ AF ablation is reasonable for patients who have symptomatic 
recurrences of AF on anti-arrhythmic therapy.
 ■ AF ablation may be considered for symptomatic long-
standing persistent AF to those refractory to class I/III anti-
arrhythmics or initially, when a rhythm control strategy is 
desired. 
 ■ It is important to take patient choice into consideration. 
Pulmonary vein isolation is the cornerstone of AF ablation; 
however, in a number of patients additional substrate modi-
fication of the left atrium may be required. Detailed description 
of these technologies is beyond the scope of this review. Key 
developments in the field of catheter ablation have been the 
addition of contact force technology to ablation catheters and 
the development of balloon based or circular ablation catheters 
with multiple ablation electrodes that can be applied to the 
pulmonary vein antrum to isolate pulmonary veins and ablate 
left atrial substrate(44,17) (Figures 1 a,b,c). 
Both radiofrequency catheter and cryoablation strategies have 
been associated with major complications including death, 
stroke, pulmonary vein stenosis, atrio-oesophageal fistula 
formation and phrenic nerve injury, amongst others. A recent 
FIGURE 1: Different strategies to AF ablation
A. Point by point ablation with irrigated radiofrequency and 3 dimensional mapping system allowing the reconstruction of 3D geometry. 
Catheter contact is visible as well (Smart Touch, CARTO 3, Biosense Webster).  
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systematic review however, demonstrates an overall low com-
plication rate and peri-procedural mortality of catheter ablation 
of AF. As catheter technology improves, experience increases 
and ablation techniques become more refined, this continuing 
downward spiral in the incidence of complications is expected 
to increase.(45) 
There is ongoing controversy over the optimal method of AF 
ablation, especially in patients with persistent or long standing 
persistent AF, and there is certainly evidence to support less 
atrial ablation.(46)
A recent concern with ablation has been silent cerebral emboli. 
This complication appears to have been more common with 
non-irrigated multi-electrode catheters, but there have been 
improvements in design to prevent this.(47)
Registry data suggests that AF ablation may reduce the risk of 
stroke;(48) however, data from randomised trials, such as 
CABANA and EAST, will be important in clarifying whether 
AF ablation has an impact on long term morbidity and mor-
tality. Currently anticoagulation is generally continued long term 
in patients with high CHA2DS2VaSc scores, even if there has 
been complete abolition of symptoms. This is because of the 
fact that some patients still get asymptomatic AF and may still 
have a risk of thromboembolism. Although there is data that 
indicates that the cessation of anticoagulation therapy may be 
safe,(17) more data is required to affirm this. Indeed, discon-
tinuation of anticoagulation is not an indication for AF abla-
tion. Patients with heart failure appear to benefit from AF 
ablation, especially those who have tachycardia-induced cardio-
myopathy, and certain subgroups should be considered for an 
interventional approach early on.(49,50)
SUMMARY
The incidence of non-valvular AF is increasing and will continue 
to contribute to morbidity and mortality. This is increasingly 
true, also for countries where communicable diseases were 
more prevalent as there has been a major change in lifestyle. 
Anticoagulation is the cornerstone, with rate and rhythm 
control strategies dependent on symptoms and quality of life.
Conflict of interest: none declared.
FIGURE 1: Different strategies to AF ablation
B. Wide area circumferential ablation (WACA) and carina at 
the junction of the left superior/inferior veins and left atrial 
appendage using a phased multi-electrode irrigated catheter 
(nMARQ, CARTO 3, Biosense Webster). 
C. Cryoablation with a cryoballoon attached to the left superior 
pulmonary vein ostium (Artic Front, Medtronic).
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